Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform


Out of Business LATEST DEAL TYPE

Developer of veterinary drugs designed to offer support to treat and cure canine cancer. The company's drug is made by using a comparative oncology approach to identify and validate human cancer drugs that have significant potential for the treatment of cancer in the dog, enabling physicians to ensure efficient treatment and faster recovery of dogs suffering from cancer.

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • 138 Allee Des Lucioles
  • Chateauneuf Villevieille
  • 06390 Nice
  • France

+33 06 00 00 00 00
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore OncoBioTek’s full profile, request a free trial.

OncoBioTek Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 01-Sep-2018 Completed Out of Business
2. Angel (individual) Cancelled Generating Revenue/Not Profitable
1. Early Stage VC Completed Generating Revenue/Not Profitable
To view this company’s complete deal history including valuation and funding, request access »

OncoBioTek Executive Team (3)

Name Title Board
Tony Dutton Chief Executive Officer & Board Member
Robert Barthel Ph.D Founder, Board Member and Chief Scientific Officer

1 Former Executive

You’re viewing 2 of 3 executives. Get the full list »

OncoBioTek Board Members (5)

Name Representing Role Since Contact
Berndt Modig Self Board Member 000 0000
Michele Garufi Self Board Member 000 0000
Robert Barthel Ph.D OncoBioTek Founder, Board Member and Chief Scientific Officer 000 0000
Tony Dutton OncoBioTek Chief Executive Officer & Board Member 000 0000
Zsolt Lavotha Self Chairman 000 0000